Results 221 to 230 of about 6,578,993 (340)

Engineering TCR-directed T-cells for the treatment of multiple myeloma. [PDF]

Front Immunol
Mubin N, Ignatz-Hoover JJ, Driscoll JJ.
europepmc   +1 more source

Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

British Journal of Haematology, EarlyView.
Summary Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma.
Gurmukh Singh
wiley   +1 more source

Recommendations for the diagnosis of extramedullary multiple myeloma. [PDF]

Chin Med J (Engl)
Shen K, Sun C, Fu W, Zou D, Gao W, An G, Wang L, Li J.   +7 more
europepmc   +1 more source

Circulating levels of insulin‐like growth factor I (IGF‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study

British Journal of Haematology, EarlyView.
Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified ...
Yolanda Benavente, Sara Hermosa, Nikos Papadimitriou, Alyssa Clay‐Gilmour, Elizabeth E. Brown, Jonathan N. Hofmann, Nathaniel Rothman, Qing Lan, Sonja I. Berndt, Demetrius Albanes, Mark Purdue, Mitchell J. Machiela, Stephen J. Chanock, Parveen Bhatti, Wendy Cozen, Aaron Norman, Susan L. Slager, James R. Cerhan, Vincent Rajkumar, Shaji K. Kumar, Celine M. Vachon, Anne J. Novak, Thomas M. Habermann, Brian K. Link, Gilles Salles, Herve Ghesquieres, Paige M. Bracci, Elizabeth Holly, Rosalie G. Griffin, Michelle A. T. Hildebrandt, Roel C. H. Vermeulen, P. Martijn Kolijn, Henrik Hjalgrim, Karin Ekström Smedby, Harindra Jayasekara, Simon Cheah, Alain Monnereau, Yu Chen, Alan Arslan, Yawei Zhang, Nicola J. Camp, Douglas W. Sborov, Afaf E. G. Osman, Elad Ziv, Immaculata De Vivo, Vijai Joseph, Lauren R. Teras, Alpa V. Patel, Eleanor Kane, Claire M. Vajdic, Adrien Guilloteau, Pierluigi Cocco, Laia Alemany, Juan Sainz, James McKay, Brenda M. Birmann, Delphine Casabonne   +56 more
wiley   +1 more source

Super-resolution binding activated localization microscopy through reversible change of DNA conformation [PDF]

, 2018
Aleksander Szczurek, Christoph Cremer, Hans Knecht, Jurek Dobrucki, Sabine Mai, Udo Birk   +5 more
core   +1 more source

Prognosis and patterns of progression in smoldering multiple myeloma. [PDF]

Blood Adv
Akhlaghi T, Maclachlan KH, Wiggins A, Usmani SZ, Derkach A, Hultcrantz M.   +5 more
europepmc   +1 more source

High‐throughput monoclonal gammopathy community monitoring programme

British Journal of Haematology, EarlyView.
Gaurav Agarwal, Lauren Campbell, Oluremi Carty, Jemma Larham, Elizabeth Knight, Sally Moore, Sarah Gooding, Jaimal Kothari, Joe Browning, Julia Evans, Lisa Ferguson, Ana Vieira, Liam Swanborough, Pamela Roberts, Elizabeth Bateman, Ross Sadler, Karthik Ramasamy   +16 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Overestimation of multiple myeloma survival from cancer registry data. [PDF]

J Natl Cancer Inst
Huber JH, Wang M, Wang R, Schoen MW, Colditz GA, Wang SY, Chang SH.   +6 more
europepmc   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source